Abstracts tagged "Disease-Modifying Antirheumatic Drugs (Dmards)"

Abstract Number: 0984 • ACR Convergence 2022
Impact of Hydroxychloroquine on Interferon Pathway Expression of SLE Phenotypic Subsets in the Absence of Background Medications
Colin Mowery, Miles Smith, Kevin Thomas, Susan Macwana, Wade deJager, Stan Kamp, Cristina Arriens, Teresa Aberle, Judith James, Joel Guthridge and Joan Merrill, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Chronic activation of interferon (IFN) pathways is a key driver of immune dysregulation in SLE. Hydroxychloroquine (HCQ) inhibits toll-like receptors 7 and 9 in…
Abstract Number: 1401 • ACR Convergence 2022
Relationship Between Disease Activity and Adverse Events of Interest in Patients with RA on Tofacitinib or TNF Inhibitors: Post Hoc Analysis of a Phase 3b/4 Randomized Safety Study
George A Karpouzas¹, Zoltan Szekanecz², Eva Baecklund³, Ted Mikuls⁴, Deepak L Bhatt⁵, Harry Shi⁶, Cunshan Wang⁷, Gosford A Sawyerr⁸, Yan Chen⁶, Sujatha Menon⁷, Carol A Connell⁷, Steven R Ytterberg⁹ and Mahta Mortezavi⁸, ¹Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²Division of Rheumatology, Faculty of Medicine, Debrecen, Hungary, ³Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ⁴Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁵Department of Cardiovascular Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁶Pfizer, Inc, Collegeville, PA, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, New York, NY, ⁹Division of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Uncontrolled RA activity and acute disease flares are associated with higher risk of adverse outcomes, such as cardiovascular (CV) disease, venous thromboembolism (VTE), malignancy,…
Abstract Number: 1737 • ACR Convergence 2022
In Vitro Response to Disease Modifying Antirheumatic Drugs Link Molecular Drug Target with Synovial Transcriptional Signature
Mads Brüner¹, Ulvi Ahmadov¹, Morten Aagaard Nielsen², Lasse Sommer Kristensen¹ and Tue Kragstrup³, ¹Department of Biomedicine, Aarhus University, Aarhus, Denmark, ²Department of Biomedicine, Aarhus University, and Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Aarhus University, Aarhus, Denmark
Background/Purpose: Immune-mediated inflammatory arthritis (IMIA) is a group of diseases characterized by chronic synovitis including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and spondyloarthritis (SpA). Some…
Abstract Number: 1992 • ACR Convergence 2022
Burden of Pain for Patients in the CorEvitasTM Rheumatoid Arthritis Registry
Joshua Baker¹, J Morel Symons², Jud C Janak³, Page Moore³, Elizabeth Kohl³, Bernice Gershenson³, Oksana Pugach³, Dave Webb⁴, Alan A Martin⁴, Didier Saurigny⁵ and Marguerite Bracher⁵, ¹University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ²GlaxoSmithKline, Collegeville, PA, ³CorEvitas, LLC, Waltham, MA, ⁴GlaxoSmithKline, Brentford, United Kingdom, ⁵GlaxoSmithKline, Stevenage, United Kingdom
Background/Purpose: Pain is a hallmark symptom of RA that impacts patients' quality of life and informs therapeutic decisions that aim to reduce joint inflammation and…
Abstract Number: PP25 • ACR Convergence 2022
From Denial of Spondyloarthritis to Becoming a Support Group Leader and Medical Doctor of Rheumatology: A Patient’s Perspective
Shung Chiu¹ and Mei Nee Chiu², ¹Spondylitis Association of America, Ludhiana, Punjab, India, ²University Institute of Pharmaceutical Sciences, Panjab University, Ludhiana, Punjab, India
Background/Purpose: From being a table tennis champion to getting into medical school, I thought my life was smooth sailing. But little did I know it…
Abstract Number: 0029 • ACR Convergence 2022
Characterizing the Anti-fibrotic Effect of Tofacitinib in TGF-β Stimulated Fibroblast-like Synoviocytes from Patients with OA
Sofie Falkenløve Madsen¹, Sarah Madsen², Elle Hollaar³, Thorbjørn Gantzel⁴, Anne-Christine Bay-Jensen³ and Christian Thudium³, ¹University of Copenhagen / Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience, University of Copenhagen, Herlev, Denmark, ³Nordic Bioscience, Herlev, Denmark, ⁴Gentofte Hospital, Gentofte, Denmark
Background/Purpose: Many osteoarthritis (OA) patients develop fibrosis of the synovial membrane leading to joint swelling, stiffness, and pain. Synovial fibroblasts activated in the synovial membrane…
Abstract Number: 0280 • ACR Convergence 2022
Safety of Filgotinib in Patients with RA: Laboratory Analysis Results from a Long-Term Extension Study
Maya Buch¹, James Galloway², Ennio Giulio Favalli³, Arnaud Constantin⁴, Patrick Durez⁵, Paul Van Hoek⁶, Christopher Watson⁷, Pieter-Jan Stiers⁶, Vijay Rajendran⁸, Katrien Van Beneden⁶, Tsutomu Takeuchi⁹ and BERNARD COMBE¹⁰, ¹University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, ²King's College London, London, United Kingdom, ³University of Milan, ASST Gaetano Pini-CTO Institute, Milano, Italy, ⁴Toulouse University Hospital and University Toulouse III Paul Sabatier, Toulouse, France, ⁵Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ⁶Galapagos NV, Mechelen, Belgium, ⁷Galapagos Biotech Ltd, Cambridge, United Kingdom, ⁸Galapagos NV, Gent, Belgium, ⁹Keio University and Saitama Medical University, Tokyo, Japan, ¹⁰Montpellier University, Montpellier, France
Background/Purpose: Filgotinib (FIL) is a Janus kinase (JAK) 1 preferential inhibitor, approved for treatment of moderate to severe active RA in Europe, the UK, and…
Abstract Number: 0384 • ACR Convergence 2022
Inflammation Is Associated with Incident Hypertension in Patients with Axial Spondyloarthritis: A Longitudinal Cohort Study
Jenny Lin Hong Shi¹, Steven H Lam², Ho So³, Edmund Li¹, Tena Li¹, Cheuk Chun Szeto¹ and Lai-shan Tam¹, ¹The Chinese University of Hong Kong, Hong Kong, China, ²The Chinese university of Hong Kong, Hong Kong, Hong Kong, ³The Faculty of Medicine, CUHK, Hong Kong, Hong Kong
Background/Purpose: In the general population, hypertension (HT) is reported as one of the most important risk and modifiable factors to develop CVD. It is well…
Abstract Number: 0747 • ACR Convergence 2022
Methotrexate and Hydroxychloroquine Used as Single Agent May Diminish Breakthrough Infection After COVID-19 Vaccination
Haihui Wang¹ and Andras Perl², ¹Upstate Medical University, Fayetteville, NY, ²SUNY, Syracuse, NY
Background/Purpose: Immunosuppressive medications generally predispose patients to greater risk of serious complications upon COVID-19 infection. This study was initiated to assess whether individual drugs may…
Abstract Number: 0915 • ACR Convergence 2022
Methotrexate Therapy Results in Disparate Methotrexate Polyglutamate Profiles in Peripheral Blood Mononuclear Cells Compared with Erythrocytes
Renske Hebing¹, Marry Lin², Sohaila Mahmoud³, Ittai B. Muller², Sandra Heil⁴, Pieter Griffioen⁴, Eduard A. Struys², Willem Lems⁵, Bart van den Bemt⁶, Michael Nurmohamed⁷, Gerrit Jansen⁸ and Robert De Jonge⁹, ¹Amsterdam Rheumatology and immunology Center, Amsterdam UMC – location Reade, Amsterdam, Netherlands, ²Department of Clinical Chemistry, Amsterdam University Medical Centers – location VUMC, Amsterdam, Netherlands, ³Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, ⁴Department of Clinical Chemistry, Erasmus MC, Rotterdam, Netherlands, ⁵Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁶Department of Pharmacy, Sint Maartenskliniek, Ubbergen, Netherlands, ⁷Amsterdam University Medical Center, Kortenhoef, Netherlands, ⁸Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers – location VUMC, Amsterdam, Netherlands, ⁹Department of Clinical Chemistry, Amsterdam University Medical Centers, Amsterdam, Netherlands
Background/Purpose: Analyses of methotrexate polyglutamates (MTX-PGs) in red blood cells (RBCs) has been employed as tool for personalized therapy approach for RA patients during MTX…
Abstract Number: 0996 • ACR Convergence 2022
Tapering of Corticosteroids or Immunosuppressive Therapy in Stable SLE: A Comparison of Complete Remission, Clinical Remission and Lupus Low Disease Activity State in Protection Against Flares
Jiacai Cho¹, liang shen², Molla Huq³, Rangi Kandane-Rathnayake⁴, Vera Golder⁴, Worawit Louthrenoo⁵, Yi-Hsin Chen⁶, Laniyati Hamijoyo⁷, Luo Shue Fen⁸, Yeong-Jian Wu⁸, Leonid Zamora⁹, Zhouli Zhang¹⁰, An Yuan¹¹, Sargunan Sockalingam¹², Yasuhiro Katsumata¹³, Masayoshi Harigai¹³, Yanjie Hao³, Zhanguo Li¹⁴, Duminda Basnayake¹⁵, Madelynn Chan¹⁶, Jun Kikuchi¹⁷, Tsutomu Takeuchi¹⁸, Sang-Cheol Bae¹⁹, Fiona Goldblatt²⁰, Shereen Oon²¹, Sean O'Neill²², Kathy Gibson²², Kristine Ng²³, Hui Nee Annie Law²⁴, Nicole Tugnet²⁵, Sunil Kumar²⁶, Cherica Tee²⁷, Michael Tee²⁷, Naoaki Ohkubo²⁸, Yoshiya Tanaka²⁸, Sandra Navarra²⁹, Chak Sing³⁰, Alberta Hoi³¹, Eric Morand³², Mandana Nikpour³³ and Aisha Lateef³⁴, ¹National University Health System (NUHS), Singapore, Singapore, ²National University of Singapore, Singapore, Singapore, ³The University of Melbourne, Melbourne, Australia, ⁴Monash University, Clayton, Australia, ⁵Chiang Mai University, Chiang Mai, Thailand, ⁶Taichung Veterans General Hospital, Taichung, Taiwan, ⁷Hasan Sadikin Hospital, Jakarta Selatan, Indonesia, ⁸Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁹University of Santo Tomas Hospital, Manila, Philippines, ¹⁰Peking University First Hospital, Beijing, China, ¹¹Peking University Health Science Center, Beijing, China, ¹²University of Malaya, Kuala Lumpur, Malaysia, ¹³Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ¹⁴People's Hospital, Peking University Health Science Center, Beijing, China, ¹⁵Teaching Hospital Kandy, Kandy, Sri Lanka, ¹⁶Tan Tock Seng Hospital, Singapore, Singapore, ¹⁷Keio University, Tokyo, Japan, ¹⁸Keio University and Saitama Medical University, Tokyo, Japan, ¹⁹Hanyang University Medical Center, Seoul, Republic of Korea, ²⁰Royal Adelaide Hospital and Flinders Medical Centre, Adelaide, Australia, ²¹St Vincent's Hospital, Fitzroy, Australia, ²²Liverpool Hospital, Sydney, Australia, ²³North Shore Hospital, Auckland, New Zealand, ²⁴Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ²⁵Greenlane Clinical Centre, Auckland, New Zealand, ²⁶Middlemore Hospital, Auckland, New Zealand, ²⁷University of the Philippines, Quezon City, Philippines, ²⁸University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ²⁹University of Santo Tomas, Manila, Philippines, ³⁰The University of Hong Kong, Pok Fu Lam, Hong Kong, ³¹Monash Health, Melbourne, Australia, ³²Monash University, Victoria; Department of Rheumatology, Monash Health, Melbourne, Australia, ³³The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia, ³⁴National University Hospital, Singapore, Singapore
Background/Purpose: Proposed targets of SLE treatment include lupus low disease activity state (LLDAS), clinical remission and complete remission. Whether treatment can be tapered after achieving…
Abstract Number: 1402 • ACR Convergence 2022
Late Onset Rheumatoid Arthritis Has a Similar Remission Rate as Younger Onset Rheumatoid Arthritis: Results from an Ontario Rheumatoid Arthritis Registry
Xiuying Li¹, Angela Cesta¹, Mohammad Movahedi² and Claire Bombardier³, ¹University Health Network, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada
Background/Purpose: The prevalence of rheumatoid arthritis (RA) in persons 60 years or older is estimated to be 2%. Late onset rheumatoid arthritis (LORA) is a…
Abstract Number: 1761 • ACR Convergence 2022
Treatment Patterns of Disease-Modifying Anti-Rheumatic Drugs by Serostatus Among Patients with Rheumatoid Arthritis
Yinzhu Jin, Jun Liu, Rishi Desai and Seoyoung Kim, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Previous studies suggest that seropositive and seronegative rheumatoid arthritis (RA) patients may respond differently to disease-modifying anti-rheumatic drugs (DMARDs). However, little is known about…
Abstract Number: 2000 • ACR Convergence 2022
Tapering of Long-term, Low Dose Glucocorticoids in Senior Rheumatoid Arthritis Patients: Follow up of the Pragmatic, Multicentre, Placebo-controlled GLORIA Trial
Abdullah Almayali¹, Maarten Boers², Linda Hartman³, Daniela OPRIS-BELINSKI⁴, Reinhard Bos⁵, Marc Kok⁶, Jose Pereira da Silva⁷, Eduard N Griep⁸, Ruth Klaasen⁹, CF Allaart¹⁰, Paul Baudoin¹¹, Hennie Raterman¹², Zoltan Szekanecz¹³, Frank Buttgereit¹⁴, Pavol MASARYK¹⁵, Willem Lems¹⁶, Maurizio Cutolo¹⁷ and Marieke ter Wee³, ¹Amsterdam University Medical Centers, Vrije Universiteit, Purmerend, Noord-Holland, Netherlands, ²Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ³Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, Netherlands, ⁴Carol Davila University, Bucharest, Romania, ⁵Medical Centre Leeuwarden, Department of Rheumatology, Leeuwarden, Netherlands, ⁶Department of Rheumatology and Clinical immunology, Maasstad Hospital, Rotterdam, Netherlands, ⁷University of Coimbra, Rheumatology, Columbia, Portugal, ⁸Department of Rheumatology, Antonius Hospital, Leeuwarden, Netherlands, ⁹Department of Rheumatology, Meander Medical Center, Amersfoort, Netherlands, ¹⁰Leiden University Medical Center, Leiden, Netherlands, ¹¹Reumazorg Flevoland, Almere, Netherlands, ¹²Department of Rheumatology, Northwest Clinics, Alkmaar, Netherlands, ¹³Division of Rheumatology, Faculty of Medicine, Debrecen, Hungary, ¹⁴Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany, ¹⁵National Institute for the Rheumatic Diseases, Piešťany, Slovakia, ¹⁶Amsterdam University Medical Centers, Amsterdam, Netherlands, ¹⁷Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genova, Italy
Background/Purpose: Guidelines suggest glucocorticoids (GC) should be used as bridge therapy in rheumatoid arthritis (RA), but many patients are on chronic treatment, and the effects…
Abstract Number: 0046 • ACR Convergence 2022
Baricitinib Ameliorates Residual Neuropathic Pain in Collagen Antibody-Induced Arthritis Mice by Suppressing Inflammation of the Dorsal Root Ganglion
Kenta Makabe¹, Yasunori Omata¹, Hiroyuki Okada¹, Ryota Chijimatsu², Asuka Terashima¹, Fumiko Yano¹, Sakae Tanaka¹ and Taku Saito¹, ¹Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan, ²Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Okayama, Japan
Background/Purpose: In clinical trials for the treatment of rheumatoid arthritis, baricitinib was shown to significantly improve pain scores compared with anti-TNF inhibitors. This result suggests…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].